全球生物製剂市场规模、份额、趋势和成长分析报告（2026-2034）

预计生物製药市场将从 2025 年的 6,402 亿美元成长到 2034 年的 15,673.4 亿美元，2026 年至 2034 年的复合年增长率为 10.46%。

全球生物製药市场正经历显着成长，主要受对治疗慢性复杂疾病的先进治疗方法需求不断增长的推动。单株抗体、疫苗和重组蛋白等生物製药已彻底改变了肿瘤、自体免疫疾病和感染疾病的治疗方法。文明病的日益增加和医疗保健支出的不断增长也促进了市场的强劲增长。

生物技术的进步和生产过程的改进是成长要素。生物相似药的普及也提高了多个地区的市场可近性和可负担性。研发投入的增加，以及强大的临床管线，进一步加速了全球生物製药研发的创新。

随着包括基因疗法和细胞疗法在内的新一代生物製剂日益受到关注，其未来前景十分光明。新兴国家医疗基础设施的扩建将开闢新的成长途径。大规模生产和低温运输物流技术的进步可望提高分销效率。对个人化医疗的持续关注将进一步巩固生物製剂在製药业的重要地位。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球生物製剂市场：依来源划分

• 市场分析、洞察与预测
• 微生物来源
• 哺乳动物起源
• 其他的

第五章 全球生物製剂市场：依产品分类

• 市场分析、洞察与预测
• 单株抗体
• 疫苗
• 重组蛋白
• 反义和RNAi疗法
• 其他的

第六章 全球生物製剂市场：依疾病类别划分

• 市场分析、洞察与预测
• 肿瘤学
• 感染疾病
• 免疫系统疾病
• 心血管疾病
• 血液疾病
• 其他的

第七章 全球生物製剂市场：依製造商划分

• 市场分析、洞察与预测
• 外包
• 内部生产

第八章 全球生物製剂市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Samsung Biologics
  • Amgen Inc
  • Novo Nordisk A/S
  • AbbVie Inc
  • Sanofi
  • Johnson & Johnson Services Inc
  • Celltrion Healthcare Co. Ltd
  • Bristol-Myers Squibb Company
  • Eli Lilly And Company
  • F. Hoffmann La-Roche Ltd

The Biologics Market size is expected to reach USD 1567.34 Billion in 2034 from USD 640.20 Billion (2025) growing at a CAGR of 10.46% during 2026-2034.

The Global Biologics Market is growing significantly due to rising demand for advanced therapies to treat chronic and complex diseases. Biologics, including monoclonal antibodies, vaccines, and recombinant proteins, have transformed treatment approaches in oncology, autoimmune disorders, and infectious diseases. Increasing prevalence of lifestyle-related illnesses and higher healthcare expenditure are contributing to strong market expansion.

Primary growth drivers include advancements in biotechnology and improved manufacturing processes. The expansion of biosimilars has also enhanced market accessibility and affordability in several regions. Growing investments in research and development, along with strong clinical pipelines, are further supporting innovation in biologic drug development globally.

Future prospects remain highly promising as next-generation biologics, including gene and cell therapies, gain traction. Expanding healthcare infrastructure in emerging economies will open new growth avenues. Technological improvements in large-scale production and cold chain logistics are expected to enhance distribution efficiency. The continued focus on personalized medicine will further solidify biologics as a dominant segment in the pharmaceutical industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Microbial
• Mammalian
• Others

By Product

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense & RNAi Therapeutics
• Others

By Disease Category

• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Manufacturing

• Outsourced
• In-House

COMPANIES PROFILED

• Samsung Biologics, Amgen Inc, Novo Nordisk AS, AbbVie Inc, Sanofi, Johnson Johnson Services Inc, Celltrion Healthcare Co Ltd, BristolMyers Squibb Company, Eli Lilly and Company, F Hoffmann LaRoche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOLOGICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOLOGICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Recombinant Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Antisense & RNAi Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOLOGICS MARKET: BY DISEASE CATEGORY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Category
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Hematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Manufacturing
• 7.2. Outsourced Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BIOLOGICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Source
  • 8.2.2 By Product
  • 8.2.3 By Disease Category
  • 8.2.4 By Manufacturing
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Source
  • 8.3.2 By Product
  • 8.3.3 By Disease Category
  • 8.3.4 By Manufacturing
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Source
  • 8.4.2 By Product
  • 8.4.3 By Disease Category
  • 8.4.4 By Manufacturing
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Source
  • 8.5.2 By Product
  • 8.5.3 By Disease Category
  • 8.5.4 By Manufacturing
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Source
  • 8.6.2 By Product
  • 8.6.3 By Disease Category
  • 8.6.4 By Manufacturing
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BIOLOGICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Samsung Biologics
  • 10.2.2 Amgen Inc
  • 10.2.3 Novo Nordisk A/S
  • 10.2.4 AbbVie Inc
  • 10.2.5 Sanofi
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 Celltrion Healthcare Co. Ltd
  • 10.2.8 Bristol-Myers Squibb Company
  • 10.2.9 Eli Lilly And Company
  • 10.2.10 F. Hoffmann La-Roche Ltd